FI103792B1 - Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja - Google Patents

Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja

Info

Publication number
FI103792B1
FI103792B1 FI906368A FI906368A FI103792B1 FI 103792 B1 FI103792 B1 FI 103792B1 FI 906368 A FI906368 A FI 906368A FI 906368 A FI906368 A FI 906368A FI 103792 B1 FI103792 B1 FI 103792B1
Authority
FI
Finland
Prior art keywords
complexes
chelating agents
antibody conjugates
bifunctional chelating
agents compounds
Prior art date
Application number
FI906368A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI906368A0 (fi
FI103792B (fi
Inventor
Roberta C Cheng
William A Fordyce
William F Goeckeler
Jr William J Kruper
Sharon Baughman
Joseph R Garlich
Garry E Kiefer
Kenneth Mcmillan
Jaime Simon
David A Wilson
Richard Keith Frank
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of FI906368A0 publication Critical patent/FI906368A0/fi
Priority to FI953708A priority Critical patent/FI104898B/fi
Application granted granted Critical
Publication of FI103792B1 publication Critical patent/FI103792B1/fi
Publication of FI103792B publication Critical patent/FI103792B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FI906368A 1988-06-24 1990-12-21 Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja FI103792B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI953708A FI104898B (fi) 1988-06-24 1995-08-03 Menetelmä terapeuttisesti aktiivisen metallikompleksiyhdisteen valmistamiseksi

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21149688A 1988-06-24 1988-06-24
US21149688 1988-06-24
US37095689A 1989-06-21 1989-06-21
US37095689 1989-06-21
PCT/US1989/002788 WO1989012631A1 (en) 1988-06-24 1989-06-23 Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US8902788 1989-06-23

Publications (3)

Publication Number Publication Date
FI906368A0 FI906368A0 (fi) 1990-12-21
FI103792B1 true FI103792B1 (fi) 1999-09-30
FI103792B FI103792B (fi) 1999-09-30

Family

ID=26906194

Family Applications (2)

Application Number Title Priority Date Filing Date
FI906368A FI103792B (fi) 1988-06-24 1990-12-21 Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja
FI982303A FI117889B (fi) 1988-06-24 1998-10-23 Menetelmä terapeuttisesti aktiivisten, makrosyklisten bifunktionaalisten kelaatinmuodostajien komplekseja sisältävien vasta-ainekonjugaattien valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI982303A FI117889B (fi) 1988-06-24 1998-10-23 Menetelmä terapeuttisesti aktiivisten, makrosyklisten bifunktionaalisten kelaatinmuodostajien komplekseja sisältävien vasta-ainekonjugaattien valmistamiseksi

Country Status (20)

Country Link
US (1) US5435990A (el)
EP (2) EP0420942A1 (el)
JP (1) JP2831073B2 (el)
KR (1) KR0137930B1 (el)
AT (1) ATE120457T1 (el)
AU (1) AU634167B2 (el)
BR (1) BR8907507A (el)
CA (1) CA1341373C (el)
DE (2) DE68921941T2 (el)
DK (1) DK175393B1 (el)
ES (1) ES2013978A4 (el)
FI (2) FI103792B (el)
GR (1) GR900300034T1 (el)
HK (1) HK60696A (el)
HU (1) HU219485B (el)
IE (1) IE67273B1 (el)
IL (1) IL90730A0 (el)
NO (1) NO179008C (el)
NZ (1) NZ229700A (el)
WO (1) WO1989012631A1 (el)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) * 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5422096A (en) * 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
EP0430968B1 (en) * 1988-05-02 1996-11-20 PHANOS TECHNOLOGIES, Inc. Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5756065A (en) * 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
JP2930708B2 (ja) * 1988-12-23 1999-08-03 ザ ダウ ケミカル カンパニー イソチオシアナト官能化金属錯体の製造方法
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
WO1991003200A1 (en) * 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
DE3938992A1 (de) 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
AU663572B2 (en) * 1992-03-27 1995-10-12 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane derivative and its use
CA2117775A1 (en) * 1992-04-13 1993-10-28 Roberta C. Cheng Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
US5310535A (en) * 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5462725A (en) * 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
ES2156143T3 (es) * 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
CA2180662A1 (en) * 1994-01-07 1995-07-13 Ramaswamy Subramanian New polyaminocarboxylate chelators
WO1995026206A1 (en) * 1994-03-28 1995-10-05 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5582814A (en) * 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE69433534T2 (de) * 1994-09-07 2004-07-08 The Dow Chemical Co., Midland Verfahren zur herstellung von makrozyklischen agentien und ihren chelaten und konjugaten
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
TW319763B (el) 1995-02-01 1997-11-11 Epix Medical Inc
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
TR28540A (tr) * 1995-03-16 1996-09-30 Guerbet Sa Poliamine edilmis baglayicilar ve bunlarin metal kompleksleri.
EP0841951A2 (en) * 1995-06-26 1998-05-20 Concat Ltd. Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043287A2 (en) * 1998-02-25 1999-09-02 Biotraces, Inc. Phosphate-based dendrimers for bioassays
US6231832B1 (en) 1998-03-23 2001-05-15 Brookhaven Science Associates Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
US6040124A (en) * 1998-11-20 2000-03-21 Eastman Kodak Company Imaging element with biaxially oriented sheet with fluoropolymer
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US6696551B1 (en) 1999-03-23 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services 225Ac-HEHA and related compounds, methods of synthesis and methods of use
LU90544B1 (en) * 2000-03-14 2001-09-17 Europ Economic Community Bifunctional chelating agent
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
KR101155294B1 (ko) 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
NZ545176A (en) * 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
WO2002096948A2 (en) * 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6670456B2 (en) 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
CA2488682C (en) 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
WO2004097372A2 (en) * 2003-04-28 2004-11-11 The Regents Of The University Of California Element-coded affinity tags
WO2005086612A2 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
JP4912153B2 (ja) 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
NZ547591A (en) * 2003-12-04 2009-11-27 Vaccinex Inc Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
BRPI0509495A2 (pt) * 2004-02-06 2016-10-11 Nymox Corp anticorpo humanizado
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP1768558A4 (en) 2004-06-09 2009-11-25 Kereos Inc LIPOPHILES DERIVATIVES OF CHELATE MONOAMIDES
EP1778699A4 (en) * 2004-08-10 2009-02-25 Dow Global Technologies Inc TARGETING OF CHELANTS AND CHELATES
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
JP5099919B2 (ja) * 2005-11-29 2012-12-19 マリンクロッド インコーポレイテッド 二官能性金属キレートコンジュゲート
KR20080099279A (ko) * 2006-02-24 2008-11-12 말린크로트, 인코포레이티드 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트
EP1999118B1 (en) 2006-03-14 2012-10-17 Mallinckrodt LLC Metal complexes of tetraazamacrocycle derivatives
EP1993613A2 (en) * 2006-03-15 2008-11-26 Mallinckrodt, Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
JP2009544574A (ja) * 2006-06-22 2009-12-17 バクシネックス インコーポレーティッド 癌を処置するための抗ｃ３５抗体
AU2007272604B2 (en) 2006-07-10 2013-08-01 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2759549B1 (en) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
AU2007329592A1 (en) * 2006-11-21 2008-06-12 Barnes-Jewish Hospital Methods of imaging employing chelating agents
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
EP2114905B1 (en) * 2007-01-25 2015-04-15 Lumiphore, Inc. Multi-color time resolved fluorophores based on macrocyclic lanthanide complexes
JP5156733B2 (ja) * 2007-02-28 2013-03-06 国立大学法人 千葉大学 抗悪性腫瘍薬
JP2010531666A (ja) 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
JP2009215238A (ja) * 2008-03-11 2009-09-24 Osaka Univ 希土類発光プローブ
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
WO2010000714A2 (en) * 2008-07-04 2010-01-07 Oslo Universitetssykehus Hf Radioimmunoconjugate kit
US20100151591A1 (en) * 2008-10-31 2010-06-17 Butlin Nathaniel G Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
KR101253100B1 (ko) 2010-02-16 2013-04-10 경북대학교 산학협력단 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
WO2015184403A2 (en) 2014-05-30 2015-12-03 Henlius Biotech Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibodies
CN114057857A (zh) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
ES2830392T3 (es) 2014-07-23 2021-06-03 Ohio State Innovation Foundation Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72)
GB201421162D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
EP3277314A4 (en) 2015-04-03 2018-08-29 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
RU2752832C2 (ru) 2016-09-16 2021-08-09 Шанхай Хенлиус Байотек, Инк. Анти-pd-1 антитела
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
MY201065A (en) 2017-04-26 2024-02-01 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CA3087423A1 (en) 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2019240884A2 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
SG11202112100PA (en) * 2019-05-10 2021-11-29 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
MX2023005462A (es) * 2020-11-10 2023-05-22 Janssen Biotech Inc Compuestos macrociclicos y metodos para usarlos.
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
SE8301395L (sv) * 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3772785D1 (de) * 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5006643A (en) * 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
ZA894792B (en) * 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates

Also Published As

Publication number Publication date
DE68921941T2 (de) 1995-07-27
HU894432D0 (en) 1992-02-28
FI982303A0 (fi) 1998-10-23
GR900300034T1 (en) 1991-07-31
IL90730A0 (en) 1990-01-18
IE892045L (en) 1989-12-24
FI906368A0 (fi) 1990-12-21
FI982303A (fi) 1998-10-23
DE353450T1 (de) 1990-09-06
DK49390A (da) 1990-02-23
DK49390D0 (da) 1990-02-23
AU634167B2 (en) 1993-02-18
US5435990A (en) 1995-07-25
NO179008B (no) 1996-04-09
KR0137930B1 (en) 1998-05-15
CA1341373C (en) 2002-07-02
EP0353450B1 (en) 1995-03-29
NO900869D0 (no) 1990-02-23
JPH04504247A (ja) 1992-07-30
ES2013978A4 (es) 1990-06-16
KR900701765A (ko) 1990-12-04
NO179008C (no) 1996-07-17
ATE120457T1 (de) 1995-04-15
IE67273B1 (en) 1996-03-20
FI103792B (fi) 1999-09-30
NZ229700A (en) 1993-01-27
HUT70200A (en) 1995-09-28
HU219485B (hu) 2001-04-28
EP0353450A1 (en) 1990-02-07
DK175393B1 (da) 2004-09-20
DE68921941D1 (de) 1995-05-04
WO1989012631A1 (en) 1989-12-28
HK60696A (en) 1996-04-19
BR8907507A (pt) 1991-06-11
JP2831073B2 (ja) 1998-12-02
EP0420942A1 (en) 1991-04-10
AU3979489A (en) 1990-01-12
FI117889B (fi) 2007-04-13
NO900869L (no) 1990-04-11

Similar Documents

Publication Publication Date Title
FI103792B1 (fi) Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja
FI944973A0 (fi) Karboksiamidimodifioituja polyamiinikelaatinmuodostajia ja radioaktiivisia komplekseja ja konjugaatteja
ZA894792B (en) Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
NO178571C (no) Analogifremgangsmåte for fremstilling av et bifunksjonelt chelateringsmiddel
FI953708A0 (fi) Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi

Legal Events

Date Code Title Description
FG Patent granted

Owner name: THE DOW CHEMICAL COMPANY